Tumor M2-pyruvate kinase in stool as a biomarker for diagnosis of colorectal cancer: A meta-analysis

Journal of Cancer Research and Therapeutics

Volumn 10, Issue , 2014, Pages C225-C228

  Huang, Jin Xi ^a,b   Zhou, Yi ^b   Wang, Cheng Hu ^b   Yuan, Wei Wei ^b   Zhang, Zhan Dong ^b   Zhang, Xie Fu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Biomarker; colorectal cancer; diagnosis; meta analysis; tumor M2 pyruvate kinase

Indexed keywords

M2 PYRUVATE KINASE; PYRUVATE KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FECES ANALYSIS; HUMAN; META ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; COMPUTER PROGRAM; METABOLISM;

CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; HUMANS; PYRUVATE KINASE; ROC CURVE; SENSITIVITY AND SPECIFICITY; SOFTWARE; TUMOR MARKERS, BIOLOGICAL;

EID: 84916603407     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.145886     Document Type: Article

References (17)

1. Rossini LG, Ribeiro PA, Rodrigues FC, Filippi SS, Zago Rde R, Schneider NC, et al. Transrectal ultrasound - Techniques and outcomes in the management of intestinal endometriosis. Endosc Ultrasound 2012;1:23-35.
2. Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rösch W, et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: Prospective multicenter study. Am J Gastroenterol 2008;103:1496-504.
3. Chen L, He Y, Wu Y, Wang D, Wang Q. Expression and clinical significance of tumor M2 pyruvate kinase in colorectal cancer pa-tients. Chin J Health Lab Technol 2008;18:1830-1.
4. Parente F, Marino B, Ilardo A, Fracasso P, Zullo A, Hassan C, et al. A combination of faecal tests for the detection of colon cancer: A new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study. Eur J Gastroenterol Hepatol 2012;24:1145-52.
5. Zhang Y, Wang L, Guo JZ. The value of tumor M2 pyruvate kinase in diagnosis of colon cancer. Jiangsu Med J 2011;37:523-5.
6. Li Y, Wang JJ. Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao 2011;31:2087-9.
7. Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis 2008;10:244-8.
8. Zhang YG, Lin RZ. Significance of fecal tumor m2 pyruvate kinase for detection of gastrointestinal cancers. Chin J Gastroenterol 2007;12:465-8.
9. Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer 2007;96:1329-34.
10. Zhang JC, Wang G. Value of fecal tumor M2 pyruvate kinase in diagnosis of colorectal cancer. World Chine J Digestology 2007;15:193-6.
11. Mulder SA, van Leerdam ME, van Vuuren AJ, Francke J, van Toorenenbergen AW, Kuipers EJ, et al. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: Performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol 2007;19:878-82.
12. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 2006;12:7007-11.
13. Guan-Fu WJ, Yi-Hua LP, Xin-Min S. Evaluation of fecal tumor m2 pyruvate kinase combined with fecal occult blood test as a detecting tool for colorectal cancer. J Sun Yat Sen Univ (Med Sci) 2006;27:350-3.
14. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, et al. Faecal tumour M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer. Br J Cancer 2004;91:980-4.
15. Naumann M, Schaum B, Oremek GM, Hanisch E, Rosch W, Mossner J, et al. Faecal pyruvate kinase type M2-a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr (1946) 2004;129:1806-7.
16. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10?29.
17. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. Pyruvate kinase type M2: A crossroad in the tumor metabolome. Br J Nutr 2002;87 Suppl 1:S23-9.